Algorae Pharmaceuticals: Breakthrough Preclinical Results for Cardiovascular Drug AI-168
1AI (1AI) Share Update November 2024 Thursday 28th
Algorae Pharmaceuticals Unveils Promising Preclinical Results for AI-168
Algorae Pharmaceuticals Limited (ASX: 1AI) announces promising preclinical results for its cardiovascular drug candidate AI-168, showcasing significant cardioprotective properties.
Instant Summary:
- AI-168 outperformed FDA-approved beta blockers in three cardiovascular cell lines.
- International Patent Cooperation Treaty application filed for AI-168.
- AI-168 to be compared with cardio selective beta blockers in animal studies.
Preclinical Study Insights
Algorae Pharmaceuticals has conducted extensive preclinical studies at Monash University Victorian Heart Institute Research Laboratories, focusing on the cardioprotective qualities of AI-168. The drug candidate was tested against well-known beta blockers in three distinct cardiovascular cell lines.
In the first model, human umbilical vein endothelial cells (HUVECs) treated with Angiotensin II showed significant improvement in cell proliferation when AI-168 was applied, achieving a 94% restoration to normal levels.
In the second model, human pulmonary artery smooth muscle cells (hPASMCs) exposed to platelet-derived growth factor demonstrated an 80% normalization in cell proliferation with AI-168, outperforming beta blockers.
Finally, in the third model, AI-168 restored 68% of cardiomyoblast growth lost to doxorubicin toxicity, a common chemotherapy-induced cardiotoxicity.
Patent and Future Studies
Algorae has filed an international Patent Cooperation Treaty (PCT) application for AI-168, aiming to secure patent protection in key markets. The company plans to conduct further animal studies in collaboration with Monash University to compare AI-168 with existing cardio selective beta blockers.
The promising preclinical results of AI-168 could position Algorae Pharmaceuticals as a significant player in the cardiovascular treatment market. The potential for AI-168 to outperform existing beta blockers could lead to increased investor interest and a positive impact on the company's stock price.
Investor Reaction:
Analysts are likely to view these results favorably, given the potential for AI-168 to capture a share of the US$6.2 billion beta blocker market. However, investors will be cautious until further clinical trials confirm these findings.
Conclusion:
Investors should keep an eye on Algorae Pharmaceuticals as it progresses with AI-168. The company's strategic moves in patent protection and upcoming animal studies will be critical in determining the drug's future market potential.